Skip to main content

Table 2 Outcomes of 10 enrolled patients

From: A pilot trial of human amniotic fluid for the treatment of COVID-19

Patient Admit Initial O2 Maximum O2 Co-Rx CRP IL-6 D-dimer LDH Discharge
1 ICU ETT ECMO/Trach HCQ,  + 30%  + 38%  + 138% − 27% Alive
2 Floor NC NC HCQ N/A N/A N/A − 28% Alive
3 Floor NC ETT HCQ, Rem N/A N/A N/A − 20% Deceased
4 ICU NC NC HCQ N/A N/A N/A N/A Alive
5 ICU ETT ETT HCQ −  84% −  60% −  21% −  22% Alive
6 ICU ETT Trach HCQ-AZ − 91% 0 − 42% N/A Alive
7 ICU HFNC HFNC HCQ  + 46%  + 109%  + 818%  + 109% Alive
8 ICU NC HFNC AZ − 87% 0 0 − 21% Alive
9 ICU NC Simple mask HCQ − 80% − 20% − 28%  + 109% Alive
10 ICU HFNC ETT HCQ  + 41%  + 412%  + 33% − 30% Alive
  1. Of note, protocol change (10 cc hAF I.V.) for patients 5–10. N/A not available, ECMO extracorporeal membrane oxygenation, ETT endotracheal intubation, HFNC high flow nasal cannula, ICU intensive care unit, MACE major adverse cardiac event, NC nasal cannula, O2 oxygen, Trach tracheostomy, Co-Rx Co-treatment, HCQ hydroxychloroquine, AZ azithromycin; Rem remdesivir. Biomarker are represented as a percent change between study enrollment and termination of hAF (5 days) with focus on the last 6 patients under current protocol. CRP: C-reactive protein; IL-6: interleukin-6; LDH: lactate dehydrogenase